80,933 Shares in Liquidia Co. (NASDAQ:LQDA) Purchased by Bank of Montreal Can

Bank of Montreal Can bought a new stake in shares of Liquidia Co. (NASDAQ:LQDA) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 80,933 shares of the company’s stock, valued at approximately $952,000. Bank of Montreal Can owned 0.10% of Liquidia as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently modified their holdings of the company. Vanguard Group Inc. raised its stake in Liquidia by 3.4% in the fourth quarter. Vanguard Group Inc. now owns 3,557,296 shares of the company’s stock worth $41,834,000 after buying an additional 115,367 shares in the last quarter. LM Advisors LLC bought a new position in shares of Liquidia in the 4th quarter worth $25,948,000. Geode Capital Management LLC lifted its stake in shares of Liquidia by 8.2% during the 4th quarter. Geode Capital Management LLC now owns 1,339,254 shares of the company’s stock worth $15,753,000 after purchasing an additional 101,597 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its position in Liquidia by 9.8% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 428,570 shares of the company’s stock valued at $5,040,000 after purchasing an additional 38,313 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its stake in Liquidia by 855.3% in the third quarter. JPMorgan Chase & Co. now owns 235,393 shares of the company’s stock valued at $2,354,000 after purchasing an additional 210,753 shares during the last quarter. Hedge funds and other institutional investors own 64.54% of the company’s stock.

Liquidia Stock Up 0.3 %

Liquidia stock opened at $13.72 on Friday. Liquidia Co. has a 52 week low of $8.26 and a 52 week high of $16.81. The firm has a market cap of $1.17 billion, a price-to-earnings ratio of -8.42 and a beta of 0.23. The business’s 50-day moving average price is $14.65 and its 200 day moving average price is $12.80.

Liquidia (NASDAQ:LQDA) last posted its earnings results on Wednesday, March 19th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.08). Liquidia had a negative net margin of 765.38% and a negative return on equity of 163.21%. The firm had revenue of $2.92 million for the quarter, compared to analysts’ expectations of $4.60 million. Equities analysts expect that Liquidia Co. will post -1.51 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on LQDA shares. Scotiabank reaffirmed an “outperform” rating on shares of Liquidia in a research report on Thursday, March 20th. HC Wainwright reaffirmed a “buy” rating and issued a $29.00 price target on shares of Liquidia in a report on Thursday, March 20th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $25.00 price objective on shares of Liquidia in a report on Thursday, April 10th. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $26.63.

Insiders Place Their Bets

In other news, CFO Michael Kaseta sold 8,283 shares of the business’s stock in a transaction that occurred on Monday, April 14th. The stock was sold at an average price of $13.57, for a total value of $112,400.31. Following the completion of the sale, the chief financial officer now directly owns 396,315 shares in the company, valued at $5,377,994.55. The trade was a 2.05 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Roger Jeffs sold 14,130 shares of the stock in a transaction that occurred on Monday, April 14th. The shares were sold at an average price of $13.57, for a total value of $191,744.10. Following the transaction, the chief executive officer now owns 1,006,420 shares in the company, valued at $13,657,119.40. This trade represents a 1.38 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 33,123 shares of company stock worth $448,366. Company insiders own 30.10% of the company’s stock.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).